BPC-157, widely known in peptide circles as the “Wolverine peptide,” has become part of a growing U.S. debate over access to unapproved peptides. U.S. Health Secretary Robert F. Kennedy Jr. has supported allowing pharmacy compounding of BPC-157, while the FDA’s Pharmacy Compounding Advisory Committee voted to recommend inclusion of BPC-157 free base and BPC-157 acetate on the 503A Bulk List.
The recommendation is not the same as FDA approval, and the peptide remains supported by limited human evidence.
The issue has gained additional attention following a September 2026 preprint that found a 33-fold increase in newly documented BPC-157 users between 2020 and 2026. Researchers identified 1,039 patients with documented BPC-157 use after analyzing clinical notes from a U.S. healthcare network containing information on more than 15 million patients.
The combination of rising use, political and regulatory attention, and limited clinical evidence makes BPC-157 an important subject for current peptide research.
What Is BPC-157, the “Wolverine Peptide”?
BPC-157 is a synthetic pentadecapeptide, meaning it contains 15 amino acids. “Wolverine peptide” is an informal term for BPC-157, particularly when it is discussed alongside another research peptide called TB-500.
The term is not the scientific name of a single molecule or an FDA-approved compound.
BPC-157 has attracted interest because preclinical research has investigated its biological activity. Studies have examined areas such as:
- Tissue responses
- Vascular signaling
- Gastrointestinal models.
However, much of the evidence remains preclinical, while controlled human research is limited.
This distinction is important because promising laboratory or animal findings do not establish that the same effects occur in humans.
Why Is Robert F. Kennedy Jr. Supporting BPC-157 Compounding?
The topic of discussion involves pharmacy compounding rather than drug approval by the Food and Drug Administration.
According to Reuters, in June 2026, Kennedy publicly endorsed several peptides, including BPC-157, ahead of an FDA advisory committee meeting. Reuters reports that Kennedy was promoting broader availability of the compounds through pharmacy compounding.
The Pharmacy Compounding Advisory Committee subsequently voted to recommend inclusion of BPC-157 free base and BPC-157 acetate on the 503A Bulks List
The distinction between compounding eligibility and FDA approval is critical.
A peptide can be considered for use as a bulk drug substance in certain compounded preparations without becoming an FDA-approved drug.
What Did the FDA Advisory Committee Decide?
On July 23, 2026, the Pharmacy Compounding Advisory Committee voted on several unapproved peptides, including BPC-157, KPV, TB-500, and MOTS-c.
The committee recommended BPC-157 for inclusion on the relevant compounding list. Reuters reported that the recommendation passed by a narrow margin.
However, advisory committee recommendations are not binding on the FDA.
The FDA remains responsible for the final regulatory decision.
FDA documents also identify significant uncertainties surrounding BPC-157. The agency has cited limited safety information, potential immunogenicity concerns, and complexities involving peptide-related impurities and active pharmaceutical ingredient characterization.
Therefore, the committee’s recommendation should not be interpreted as a finding that BPC-157 has been proven safe or effective.
Why Is BPC-157 Suddenly Getting Such Attention?
BPC-157 was already well-known online before the 2026 regulatory issue.
It has been linked to everything from:
- Injury recovery
- Pain
- Soft-tissue research
- Gastrointestinal conditions
- Athletic performance
Most of these come from consumer proclamations, blogs, and preclinical investigations, rather than large-scale, well-controlled clinical trials.
Not only that, but another recent study suggests that it is on the rise.
A preprint published in September 2026 analyzed clinical notes from an American federated healthcare system. They found 1,536 patients with an appearance of BPC-157 in their notes, and 1,039 with documented use.
Documented BPC-157 Use Went Up 33-Fold
The researchers found that newly identified users rose from 4 in the first quarter of 2020 to 134 in the first quarter of 2026.
That’s a 33-fold rise.
But that doesn’t mean that overall BPC-157 use went up 33-fold in the United States.
The study only looked at documented BPC-157 use within the healthcare network.
Because there is no approved pharmaceutical compound form and no standard National Drug Code number for BPC-157, it may not appear as a standardized medication in a patient’s record.
The researchers had to look at mentions of BPC-157 inside clinical notes.
Where Are People Getting BPC-157?
The 2026 study also examined documented sources.
Source information was available for 205 of the 1,039 confirmed users.
Among those patients:
- 36% obtained BPC-157 from compounding pharmacies.
- 35% obtained it from gray-market peptide vendors.
- Other sources accounted for the remaining documented cases.
Because source information was available for only a minority of the cohort, these percentages should not be treated as representative of all BPC-157 users.
The findings nevertheless demonstrate why the regulatory debate has become more relevant.
BPC-157 use is occurring through both conventional healthcare-related channels and less-regulated peptide markets.
Why Are People Using BPC-157?
The researchers documented reasons for use in 644 patients.
The most frequently documented reasons included:
- Pain
- Gastrointestinal conditions
- Previous injuries
- Post-surgical healing
- Performance enhancement
Pain represented approximately 33% of the overall confirmed-user cohort, while gastrointestinal conditions accounted for 14%. Previous injury and post-surgical healing were also frequently documented.
These figures describe reported reasons for use, not established medical indications.
That distinction matters because an observational record showing that people use BPC-157 for a condition does not establish that the compound is effective for that condition.
What Does the New BPC-157 Study Say About Results?
The study also examined reported outcomes.
Among the 354 patients with an ascertainable directional response, 279 (78.8%) had documented symptomatic improvement.
However, these findings should be interpreted cautiously.
The study was retrospective and observational, rather than a randomized controlled clinical trial.
Patients were also using other treatments. More than half of the confirmed users, 525 patients, had documented co-use of another therapeutic agent. TB-500 was among the commonly documented co-used substances. Physical therapy, surgery, exercise counseling, and dietary counseling were also recorded as co-interventions.
As a result, the researchers could not determine whether reported improvements were caused by BPC-157.
The authors specifically state that the findings cannot distinguish BPC-157 effects from peptide combinations, other treatments, non-drug interventions, placebo effects, or selection and reporting biases.
What Are the Safety Questions Around BPC-157?
Safety remains one of the major unanswered questions.
The 2026 preprint identified documented neuropsychiatric events, injection-site hypersensitivity, and gastrointestinal events during BPC-157 use. The authors also noted that adverse events were likely underreported because the research relied on clinical documentation.
FDA materials raise additional concerns.
For BPC-157, the FDA has identified potential issues involving:
- Immunogenicity
- Peptide-related impurities
- API characterization
- Limited safety information for proposed routes of administration
The agency states that it lacks sufficient information to determine whether compounded BPC-157 could cause harm when administered to humans.
These concerns do not establish that BPC-157 causes specific adverse effects. They demonstrate why more systematic safety research is needed.
BPC-157 and TB-500: What Is the “Wolverine Stack”?
BPC-157 is also frequently discussed with TB-500, another peptide-related research compound.
The combination is commonly called the “Wolverine stack” in online peptide communities.
The two substances are distinct. “Wolverine peptide” does not refer to a standardized pharmaceutical combination containing both compounds.
Interestingly, the 2026 clinical-note study found that TB-500 was documented as a co-used therapeutic agent in 12.9% of BPC-157 users.
This demonstrates that the combination occurs in real-world use.
It does not establish that combining the two substances produces a particular biological or clinical outcome.
What Does the Existing Research Actually Show?
The current body of research includes significantly more preclinical studies than rigorous human clinical research.
Experimental studies have looked at BPC-157 on animals or cell models. Including studies on tendon and ligament models, cellular effects, gastrointestinal research, and vascular signaling.
There is far less research in humans.
The preprint of 2026 described the human research in the BPC-157 literature as limited, including small studies of knee pain, interstitial cystitis, and IV safety. These do not provide sufficient information about the drug’s clinical benefits or long-term effects.
This represents a substantial disconnect between public interest and clinical reality.
Is BPC-157 an FDA-Approved Drug?
No.
BPC-157 is not an FDA-approved drug.
In its 2026 discussion on FDA’s advisory committee, the question was whether BPC-157-containing bulk drug substances could be listed under 503A Bulks for certain compounding. This regulation differs from FDA drug compound approval of BPC-157.
This distinction is very relevant when reading 2026 advisory vote headlines.
What Could Happen Next?
The regulatory standing of BPC-157 is one area that needs to be monitored.
While the advice of the advisory committee provided a way for the further FDA review of BPC-157 compounding, the recommendation itself does not determine the stance of the FDA.
On the other hand, the scientific data keep growing.
Further research might give the answers to such questions as:
- Human pharmacokinetics
- Appropriate research dosing
- Short- and long-term safety
- Immunogenicity
- Compound characterization
- Peptide-related impurities
- Potential drug interactions
- Specific clinical indications
Prospective clinical trials will be especially useful since anecdotal reports cannot prove causation.
FAQs
1. What is the Wolverine peptide?
The term “wolverine peptide” is often used when talking about BPC-157. In discussions involving BPC-157 and TB-500, this is a very common term.
2. Why is Robert F. Kennedy Jr. supporting BPC-157?
Robert F. Kennedy Jr. supports wider access to certain peptides that have not yet been approved by the FDA. His stance is related to access and compounding policies, not to FDA evaluation of the efficacy of BPC-157.
3. Was BPC-157 approved by the FDA in 2026?
No, the recommendation of an FDA advisory panel to add BPC-157 to the 503A Bulks list is not the same as approval of BPC-157 efficacy.
4. What is the Wolverine stack?
The “Wolverine stack” refers to a mixture of BPC-157 and TB-500.
5. Did the 2026 study prove that BPC-157 works?
No. This study is observational in nature and relies heavily on clinical notes. The authors admit that their study did not prove efficacy, nor was it able to identify the role of BPC-157 in the observed results.
6. Is there any research still ongoing on BPC-157?
Yes. BPC-157 continues to appear in preclinical and limited human research, but substantial gaps remain in controlled human efficacy and safety data.
Conclusion
The support from RFK Jr. has added further attention to a peptide that had already attracted substantial interest in online and preclinical research communities.
While the July 2026 FDA advisory committee recommendation was significant progress in the compounding dispute, it should not be equated with FDA approval or clinical efficacy. The documents published by the FDA still note significant questions regarding the safety and characterization of BPC-157.
On the other hand, the September 2026 clinical-note study gives proof of a significant rise in the documented use of BPC-157. The researchers found 1,039 people who used BPC-157 and discovered a 33-fold increase in the number of newly documented users between 2020 and 2026. Nevertheless, the design of the study makes it impossible for the researchers to conclude if BPC-157 was responsible for the effects noted in the patients’ notes.
For any person interested in the Wolverine peptide research, the question that becomes apparent is the disconnect between the usage and the evidence available for clinical practice.
References
- https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/
- https://www.preprints.org/manuscript/202609.0501
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?